Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

CureVac AG. (6/12/18). "Press Release: CureVac Announces Appointment of Matthew L. S. Beck as Vice President of Investor Relations". Tübingen & Boston, MA.

Region Region United States (USA)
Organisations Organisation CureVac AG
  Group CureVac (Group)
  Organisation 2 Trout Group LLC, The
  Group Trout Group (Group)
Products Product public relations / investor relations / marcom (services)
  Product 2 mRNA-based drug
Persons Person Beck, Matthew L. S. (Matt) (CureVac 201806– VP Investor Relations before Solebury Trout)
  Person 2 Kemula, Pierre (CureVac 201610– CFO before Pixium Vision + Ipsen + Roland Berger)
     


CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the appointment of Matthew L. S. Beck as Vice President, Investor Relations. He joins CureVac from Solebury Trout, a leading investor relations firm focused on companies in the life sciences and other industries.

"We're excited to welcome Matt to the CureVac team," said Pierre Kemula, Chief Financial Officer, CureVac AG. "His experience advising senior management at numerous life sciences companies, and knowledge of the capital markets in the U.S., will be critical as we advance our business and clinical pipeline of mRNA-based therapies.”

Mr. Beck has more than 18 years of experience in the field of investor relations. Prior to serving as Senior Vice President at Solebury Trout, he was Senior Specialist at NASDAQ OMX’s Corporate Advisory division. Prior to NASDAQ OMX, he served as a Marketing Associate at Dunbar Capital, a fund of hedge funds. Prior to that, he was a Vice President in Goldman Sachs’ NYSE DMM division. Early in his career, Mr. Beck served in increasingly responsible roles at Thomson Financial. He earned a Bachelor of Arts degree in Political Science from Vassar College.


About CureVac AG

CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 18 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies.

To date, CureVac has received approximately $420 million (€400 million) in equity investments including significant investments from SAP founder Dietmar Hopp’s Dievini and an investment of $52 million from the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, Arcturus Therapeutics, Acuitas, and the Bill & Melinda Gates Foundation. For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.

***



Media Contacts

Verena Lauterbach, Senior Manager Communications
CureVac AG, Tübingen, Germany
T: +49 7071 9883 1756
verena.lauterbach@curevac.com

Rich Allan
Solebury Trout, New York, United States
T: +1 646 348-2958
rallan@troutgroup.com

Investor Contact

Matthew Beck, Vice President Investor Relations
CureVac AG, Boston, MA, United States
T: +1 917-415-1750
matthew.beck@curevac.com

   
Record changed: 2018-06-29

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for CureVac (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top